Equity
-€55,367
Debts exceed assets in financial year 2025.
ARBILUX
Lifetime
20 annual accounts with figures on one time axis, 46 filings since 1980peak €137,777 (2006)
-€2,308▼ €10,119
lowest -€166,082 (2009)
-€19,609▼ €11,427
peak €515,751 (2007)
-€55,367▼ €19,609
€248,208▲ 3.4%
peak 3.1 FTE (2006)
-not published
Board2 names since 2021
1 director
Documentsfilings and deeds
14-07-202617 days before the deadline
2025micro format
Gross margin from €7,812 to -€2,308Loss of €19,609New managing director 24-03Equity from -€35,758 to -€55,367Cash from €4,232 to €559
Key points
from the 2025 annual accountsLosses
-€109,386 in seven years
Every financial year from 2019 to 2025 closed with a loss. 2019 was the heaviest.
Debts
€248,208 129% of the balance sheet
Suppliers 2%Taxes and wages 0%Other 98%
Of this, €248,162 falls due within a year.
Turnover not published (micro format)
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,635 companies had the same profile as ARBILUX has now. Each dot stands for 17 companies, two years later.
84.3%
were still trading
10.2%
stopped another way
4.5%
went bankrupt
Another 1.0% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,635 companies, not a prediction for ARBILUX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0419806595
New managing director
appointed, resigned · General meeting of 12-03-2025 · Gazette deed
Appointments: (managing director) and (director)
General meeting of 15-11-2021 · Gazette deed
First establishment
SA AROPHAR, Chemin de la Chabotte (Petithan) 16, Durbuy
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ARBILUX Durbuy | €192,841 | -€2,308 | -28.7% | - |
| FARMACIE AN-JOLIE Tongeren | €199,800 | -€2,437 | 82.1% | 0 |
| MEDIOX Wijnegem | €214,632 | -€5,378 | 61.9% | - |
| Bogman Medical Equipment Merchtem | €274,746 | -€7,023 | 99.8% | - |
| Roller Willebroek | €167,766 | -€1,056 | 97.9% | - |
| AB2 Etterbeek | €278,131 | -€4,688 | 55.4% | - |
| MEDESTIME Charleroi | €231,746 | -€38,922 | -292.8% | - |
These companies have the same main activity as ARBILUX: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €168,000 and €278,000, founded between 1979 and 1991.
Official details
Source: KBO- Status
- Active since 03-09-1979Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Establishment unit
- 2.017.070.4586940 Durbuy, since 01-06-1989
- Financial year end
- 31 December
- Peppol
- Reachable since 27-01-2026
Annual accounts 2025
- €192,841▼ 5.6%
- Filing
- Filed on 14-07-2026, 17 days before the end of the filing period
Insights on ARBILUX
ARBILUX files the micro format. That format states no turnover. The gross margin fell from €137,777 in 2006 to -€2,308 in 2025.
The balance sheet grew most in 2007 through fixed assets.
In March 2025, the Official Gazette published the appointment of as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ARBILUX
- What is the company number of ARBILUX?
- The company number of ARBILUX is 0419.806.595. The VAT number is the same number with BE in front: BE 0419.806.595.
- Where is ARBILUX based?
- The registered office is at Chemin de la Chabotte (Petithan) 16, 6940 Durbuy.Company details
- What does ARBILUX do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of ARBILUX?
- ARBILUX is a public limited company (NV).
- When was ARBILUX founded?
- ARBILUX was founded on 03-09-1979.
- Is ARBILUX still active?
- Yes, ARBILUX is an active enterprise in the KBO register.
- What is the turnover of ARBILUX?
- The annual accounts for financial year 2025 state no turnover. The micro format does not require it.Financials
- Is ARBILUX profitable?
- In financial year 2025, ARBILUX made a loss of €19,609.
- Where can I find the annual accounts of ARBILUX?
- ARBILUX filed 46 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ARBILUX due?
- ARBILUX must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.